- Home
- CAG vs IBRX Comparison
CAG vs IBRX Comparison
Compare CAG & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAG | IBRX |
|---|---|---|
| Founded | 1919 | 2014 |
| Country | United States | United States |
| Employees | 26100 | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 7.5B |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CAG | IBRX |
|---|---|---|
| Price | $14.12 | $7.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 7 |
| Target Price | ★ $16.88 | $12.57 |
| AVG Volume (30 Days) | 14.1M | ★ 14.7M |
| Earning Date | 04-01-2026 | 05-11-2026 |
| Dividend Yield | ★ 9.71% | N/A |
| EPS Growth | ★ 233.33 | 38.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,500,000,000.00 | $113,288,000.00 |
| Revenue This Year | N/A | $88.59 |
| Revenue Next Year | N/A | $131.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $14.04 | $1.83 |
| 52 Week High | $24.80 | $12.43 |
Technical Indicators
Market Signals| Indicator | CAG | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 31.02 | 46.98 |
| Support Level | $14.04 | $2.22 |
| Resistance Level | $19.54 | $8.28 |
| Average True Range (ATR) | 0.41 | 0.56 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 4.74 | 39.03 |
Price Performance
Historical ComparisonAbout CAG ConAgra Brands Inc.
Conagra Brands is a packaged food company that operates predominantly in the United States (91% of fiscal 2025 revenue). Most of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, and Wish-Bone. The company primarily sells through the US retail channel, with just 9% of fiscal 2025 revenue coming from international markets and 9% from foodservice.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.